-- 週四,受中國製造業成長放緩以及勞動節假期臨近的影響,中國股市漲跌互現。 衡量中國股市的主要指標-上證綜指上漲0.1%,收在4112.16點。深證成指下跌0.1%,收在15107.55點。 4月中國製造業採購經理人指數(PMI)季減0.1個百分點,至50.3%。 生產和新訂單分項指數分別維持在51.5%和50.6%的臨界點以上。其他分項指數如原材料、就業和供應商交貨時間則分別低於臨界點,分別為49.3%、48.8%和49.5%。 同時,非製造業商業活動指數為49.4%,季減0.7個百分點。綜合PMI產出指數為50.1%,下降0.4個百分點。 公司新聞方面,浙江世紀華通集團(SHE:002602)公佈第一季歸屬於母公司股東的淨利為20.3億元人民幣,較上年同期的13.5億元人民幣成長35%。這家遊戲開發商的股價週四下跌了9%。
Related Articles
Berenberg Adjusts Estimates for Galp Energia After 'Solid' Q1 Results; Hold Rating Maintained
Berenberg updated its earnings forecasts for Galp Energia (GALP.LS) after the Portuguese energy company reported its first-quarter results."Galp reported a solid set of results for Q126 on 27 April from an operational point of view, and beat consensus EBITDA expectations, although this was offset by some cash flow adjustments in the period. Delivery of the important Bacalhau project (Brazil) appears to be ahead of expectations, and, after a strong Q1 in the refining business, Galp is moving towards confirming the terms of its downstream merger with Moeve. In the earnings call, the company indicated that its 2026 guidance is now likely out of date given the macro backdrop, and that it may update its FY26 outlook in the Q2 results. We leave our Hold rating and EUR20 price target unchanged," the research firm said Wednesday.Against this backdrop, the research firm increased its 2026 EBITDA assumption by 3%, while cutting its cash flow from operations and free cash flow estimates by 4% and 3%, respectively, to account for a recent 320 million-euro renewable acquisition and other liquidity adjustments.Meanwhile, analysts maintained their share repurchase projection for 2026 at 250 million euros, while boosting their 2027 forecast to 455 million euros, which is 10% above consensus. Berenberg's EPS estimates for 2026 through 2028 were also revised upwards.
Henlius Biotech Doses First Patient in Lung Cancer Drug Trial in China
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX3901 in mainland China, according to a Thursday Hong Kong bourse filing.The drug is being tested for the treatment of patients with advanced small-cell lung cancer or neuroendocrine carcinoma.
BP Confirms Preliminary Offshore Exploration Agreement With Venezuela
BP (BP.L) entered into a memorandum of understanding with the Bolivarian Republic of Venezuela to establish "potential areas for co‑operation in material offshore gas and future exploration," according to a statement sent toon Thursday.Venezuela's Acting President Delcy Rodríguez announced in a Wednesday signing event its offshore natural gas exploration deal with the British oil major, which covers the Deltana Platform, an oil and natural gas reservoir in the nation's eastern waters, according to a same-day report from Bloomberg News.BP Executive Vice President William Lin also said the company plans to launch a permanent regional office in Caracas, Venezuela.